Related Experiment Video
Updated: Aug 30, 2026
Extrahepatic Bile Duct and Gall Bladder Dissection in Nine-Day-Old Mouse Neonates
Published on: August 23, 2022
Biliary atresia
Barbara Anne Haber1, Pierre Russo
1Division of Gastroenterology and Nutrition, Children's Hospital of Philadelphia, 34th and Civic Center Boulevard, Philadelphia, PA 19104, USA.
Insights
Biliary Atresia (BA) significantly impacts pediatric hepatology as a leading cause of neonatal cholestasis and a primary reason for liver transplants. A new national initiative aims to improve BA treatment and understand its causes.
Area of Science:
- Pediatric Hepatology
- Neonatal Cholestasis
- Liver Transplantation
Background:
- Biliary Atresia (BA) is a rare disease with unknown causes.
- It is the most frequent surgically correctable cause of neonatal cholestasis.
- BA is the most common pediatric liver disease requiring transplantation.
Purpose of the Study:
- To address the lack of progress in improving outcomes and understanding BA pathogenesis.
- To introduce a new national, government-sponsored collaborative effort.
- To drive advancements in BA treatment and pathogenesis research.
Main Methods:
- A national, government-sponsored collaborative endeavor has been initiated.
- Focus on designing new treatments for BA.
- Emphasis on developing a better understanding of BA pathogenesis.
Main Results:
- No specific results are detailed in the abstract.
- The abstract highlights the initiation of a collaborative effort.
- The expected impact on treatment and understanding is emphasized.
Conclusions:
- BA remains a significant challenge in pediatric hepatology.
- Current understanding and treatment outcomes for BA have seen limited progress.
- A new national collaborative initiative holds promise for future advancements in BA research and patient care.
Abstract:
BA is a rare disease of unclear etiology; nevertheless, its impact in the field of pediatric hepatology is significant. It is the most common surgically correctable cause of neonatal cholestasis and is the most common pediatric disease referred for liver transplantation. Little progress has been made with regard to improving outcome or understanding its pathogenesis in the past decade. Fortunately, however, a national, government-sponsored collaborative endeavor has begun that will hopefully make a significant impact upon the progress of designing new treatments for BA and develop a better understanding of its pathogenesis.
